Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We utilise our cutting-edge, exclusive workflow to develop focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q9C093
UPID:
SPEF2_HUMAN
Alternative names:
Protein KPL2
Alternative UPACC:
Q9C093; Q2TAC9; Q96LL6; Q9H5C7; Q9H5Q7
Background:
Sperm flagellar protein 2, also known as Protein KPL2, plays a pivotal role in male fertility. It is essential for the correct development of the axoneme in spermatozoa, crucial for sperm motility and morphology. This protein is involved in the localization of the intraflagellar transport protein IFT20, indicating its role in dynein-mediated protein transport during spermatogenesis. Additionally, it contributes to bone growth by supporting normal osteoblast differentiation.
Therapeutic significance:
Sperm flagellar protein 2 is linked to Spermatogenic failure 43, an autosomal recessive infertility disorder characterized by asthenospermia due to various sperm flagella abnormalities. Understanding the role of Sperm flagellar protein 2 could open doors to potential therapeutic strategies for treating infertility issues related to sperm motility and morphology.